LOW-DOSE LENALIDOMIDE AND CYTARABINE COMBO PRODUCES A HIGH COMPLETE REMISSION RATE THAT CAN BE PREDICTED BY GENETIC PROFILING IN AML PATIENTS AGED >= 70 YEARS: FINAL RESULTS OF A PHASE II STUDY

Isidori A;Ferrara F;DI RAIMONDO, FRANCESCO;Loscocco F;Fuligni F;Gazzola A;Rossi M;Laginestra A;Caraci MR;Zammit V;Spina E;Sparaventi G;Malerba L;Rocchi M;Gabucci E;Clissa C;Piccaluga PP;Visani G.

2015-01-01